Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01077323 · ClinicalTrials.gov registry record
A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 363,766
- Enrollment target
NCT01077323 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 363,766 participants.
The verdict
NCT01077323 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 363,766 participants
- Enrollment target
Study Summary
The purpose of this research was to assess the absolute and relative incidence of acute pancreatitis in persons initiating exenatide compared with persons initiating a different antidiabetic agent, and secondarily, persons without diabetes. This protocol summarizes a retrospective cohort study using eligibility, pharmacy claims, and medical claims data from a large US health plan affiliated with i3 Drug Safety.
Interventions
- DRUG exenatide
- DRUG Other antidiabetic therapies
- OTHER No diabetes therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 363,766 participants |
| Start Date | 2004-09 |
| Est. Completion | 2008-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01077323
The ClinicalTrials.gov registry entry for NCT01077323 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 363,766 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which exenatide is the first listed.
NCT01077323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01077323 about?
NCT01077323 is a clinical study titled "A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents". The purpose of this research was to assess the absolute and relative incidence of acute pancreatitis in persons initiating exenatide compared with persons initiating a different antidiabetic agent, and secondarily, persons without diabetes. This protocol summarizes a retrospective cohort study using...
What is the current status of trial NCT01077323?
This trial is currently completed. The enrollment target is 363,766 participants. The study started on 2004-09. Estimated completion is 2008-03.
What interventions are being tested in trial NCT01077323?
The interventions under investigation include: exenatide (DRUG), Other antidiabetic therapies (DRUG), No diabetes therapy (OTHER).
Who is sponsoring clinical trial NCT01077323?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.